In Vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice

Marine Drugs

Volumn 10, Issue 9, 2012, Pages 2055-2068

  Wang, Jun ^a   Chen, Shihui ^a   Xu, Shiqiang ^a   Yu, Xing ^a   Ma, Dongqing ^a   Hu, Xiamin ^a   Cao, Xiaolu ^a  

^a WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antitumor; Epidermal growth factor receptor; Fucoxanthin; Marine natural products; Signal transducers and activators of transcription 3

Indexed keywords

CASPASE 3; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FUCOXANTHIN; PROTEIN BCL 2; SOYBEAN OIL; STAT3 PROTEIN; SURVIVIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME REPRESSION; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SARCOMA 180; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84867273775     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md10092055     Document Type: Article

References (41)

1. D'Orazio, N.; Gemello, E.; Gammone, M.A.; De Girolamo, M.; Ficoneri, C.; Riccioni, G. Fucoxantin: A treasure from the sea. Mar. Drugs 2012, 10, 604-616.
2. Peng, J.; Yuan, J.P.; Wu, C.F.; Wang, J.H. Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar. Drugs 2011, 9, 1806-1828.
3. Woo, M.N.; Jeon, S.M.; Shin, Y.C.; Lee, M.K.; Kang, M.A.; Choi, M.S. Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice. Mol. Nutr. Food Res. 2009, 53, 1603-1611.
4. Nishino, H. Cancer prevention by natural carotenoids. Mutat. Res. 1998, 402, 159-163.
5. Heo, S.J.; Yoon, W.J.; Kim, K.N.; Ahn, G.N.; Kang, S.M.; Kang, D.H.; Affan, A.; Oh, C.; Jung, W.K.; Jeon, Y.J. Evaluation of anti-inflammatory effect of fucoxanthin isolated from brown algae in lipopolysaccharide-stimulated RAW 264.7 macrophages. Food Chem. Toxicol. 2010, 48, 2045-2051.
6. Tanaka, T.; Shnimizu, M.; Moriwaki, H. Cancer chemoprevention by carotenoids. Molecules 2012, 17, 3202-3242.
7. Nishino, H. Cancer chemoprevention by natural carotenoids and their related compounds. J. Cell Biochem. Suppl. 1995, 22, 231-235.
8. Okuzumi, J.; Nishino, H.; Murakoshi, M.; Iwashima, A.; Tanaka, Y.; Yamane, T.; Fujita, Y.; Takahashi, T. Inhibitory effects of fucoxanthin, a natural carotenoid, on N-myc expression and cell cycle progression in human malignant tumor cells. Cancer Lett. 1990, 55, 75-81.
9. Liu, C.L.; Huang, Y.S.; Hosokawa, M.; Miyashita, K.; Hu, M.L. Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. Chem. Biol. Interact. 2009, 182, 165-172.
10. Satomi, Y.; Nishino, H. Implication of mitogen-activated protein kinase in the induction of G1 cell cycle arrest and gadd45 expression by the carotenoid fucoxanthin in human cancer cells. Biochim. Biophys. Acta 2009, 1790, 260-266.
11. Das, S.K.; Hashimoto, T.; Kanazawa, K. Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim. Biophys. Acta 2008, 1780, 743-749.
12. Kotake-Nara, E.; Terasaki, M.; Nagao, A. Characterization of apoptosis induced by fucoxanthin in human promyelocytic leukemia cells. Biosci. Biotechnol. Biochem. 2005, 69, 224-227. (Pubitemid 40383507)
13. Yamamoto, K.; Ishikawa, C.; Katano, H.; Yasumoto, T.; Mori, N. Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. Cancer Lett. 2011, 300, 225-234.
14. Kim, K.N.; Heo, S.J.; Kang, S.M.; Ahn, G.; Jeon, Y.J. Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol. In Vitro 2010, 24, 1648-1654.
15. Das, S.K.; Hashimoto, T.; Shimizu, K.; Yoshida, T.; Sakai, T.; Sowa, Y.; Komoto, A.; Kanazawa, K. Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim. Biophys. Acta 2005, 1726, 328-335.
16. Hosokawa, M.; Kudo, M.; Maeda, H.; Kohno, H.; Tanaka, T.; Miyashita, K. Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells. Biochim. Biophys. Acta 2004, 1675, 113-119.
17. Satomi, Y. Fucoxanthin induces GADD45A expression and G1 arrest with SAPK/JNK activation in LNCap human prostate cancer cells. Anticancer Res. 2012, 32, 807-813.
18. Zhang, Z.; Zhang, P.; Hamada, M.; Takahashi, S.; Xing, G.; Liu, J.; Sugiura, N. Potential chemoprevention effect of dietary fucoxanthin on urinary bladder cancer EJ-1 cell line. Oncol. Rep. 2008, 20, 1099-1103.
19. Yu, R.X.; Hu, X.M.; Xu, S.Q.; Jiang, Z.J.; Yang, W. Effects of fucoxanthin on proliferation and apoptosis in human gastricadenocarcinoma MGC-803 cells via JAK/STAT signal pathway. Eur. J. Pharmacol. 2011, 657, 10-19.
20. Januar, H.I.; Dewi, A.S.; Marraskuranto, E.; Wikanta, T. In silico study of fucoxanthin as a tumor cytotoxic agent. J. Pharm. Bioallied Sci. 2012, 4, 56-59.
21. Quesnelle, K.M.; Boehm, A.L.; Grandis, J.R. STAT-Mediated EGFR signaling in cancer. J. Cell Biochem. 2007, 102, 311-319. (Pubitemid 47519405)
22. Cheong, J.H.; Hong, S.Y.; Zheng, Y.; Noh, S.H. Eupatilin inhibits gastric cancer cell growth by blocking STAT3-mediated VEGF expression. J. Gastric Cancer 2011, 11, 16-22.
23. Sinibaldi, D.; Wharton, W.; Turkson, J.; Bowman, T.; Pledger, W.J.; Jove, R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling. Oncogene 2000, 19, 5419-5427. (Pubitemid 32000908)
24. Niu, G.; Wright, K.L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; Heller, R.; Ellis, L.M.; Karras, J.; Bromberg, J.; Pardoll, D.; Jove, R.; Yu, H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21, 2000-2008. (Pubitemid 34270888)
25. Jorissen, R.N.; Walker, F.; Pouliot, N.; Garrett, T.P.; Ward, C.W.; Burgess, A.W. Epidermal growth factor receptor: mechanisms of activation and signaling. J. Exp. Cell Res. 2003, 284, 31-53. (Pubitemid 36331965)
26. Chan, K.S.; Cabajal, S.; Kiguchi, K. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. J. Cancer Res. 2004, 64, 2382-2389. (Pubitemid 38523890)
27. Song, J.I.; Grandis, J.R. STAT signaling in head and neck cancer. Oncogene 2000, 19, 2489-2495. (Pubitemid 30339204)
28. Berclaz, G.; Altermatt, H.J.; Rohrbach, V.; Siragusa, A.; Dreher, E.; Smith, P.D. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int. J. Oncol. 2001, 19, 1155-1160.
29. Sun, J.; Zhao, L.; Teng, L.; Lin, F.; Zhang, H.; Li, Z.; Gao, Q. Solid tumor-targeted infiltrating cytotoxic T lymphocytes retained by a superantigen fusion protein. PLoS One 2011, 6, e16642.
30. Kanwar, J.R.; Kamalapuram, S.K.; Kanwar, R.K. Survivin signaling in clinical oncology: A multifaceted dragon. Med. Res. Rev. 2012, doi:10.1002/med.21264.
31. Church, D.N.; Talbot, D.C. Survivin in solid tumors: rationale for development of inhibitors. Curr. Oncol. Rep. 2012, 14, 120-128.
32. Takezawa, K.; Okamoto, I.; Nishio, K.; Jänne, P.A.; Nakagawa, K. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin. Cancer Res. 2011, 17, 2140-2148.
33. Cao, Y.; Guangqi, E.; Wang, E.; Pal, K.; Dutta, S.K.; Bar-Sagi, D.; Mukhopadhyay, D. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 2012, 72, 3912-3918.
34. Rahmani, A.; Alzohairy, M.; Khadri, H.; Mandal, A.K.; Rizvi, M.A. Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke. Int. J. Clin. Exp. Pathol. 2012, 5, 195-202.
35. Su, L.; Rao, K.; Guo, F.; Li, X.; Ahmed, A.A.; Ni, Y.; Grossmann, R.; Zhao, R. In ovo leptin administration inhibits chorioallantoic membrane angiogenesis in female chicken embryos through the STAT3-mediated vascular endothelial growth factor (VEGF) pathway. Domest. Anim. Endocrinol. 2012, 43, 26-36.
36. Calo, V.; Migiliavacca, M.; Bazan, V. STAT proteins: from normal control of cellular events totumorigenesis. J. Cell Phisiol. 2003, 97, 157-168. (Pubitemid 37485244)
37. Al Zaid Siddiquee, K.; Turkson, J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008, 18, 254-267. (Pubitemid 351206162)
38. Lee, T.L.; Yeh, J.; Van Waes, C.; Chen, Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol. Cancer Ther. 2006, 5, 8-19.
39. Baba, Y.; Fujii, M.; Tokumaru, Y.; Kato, Y. Present and future of EGFR inhibitors for head and neck squamous cell cancer. J. Oncol. 2012, 2012, doi:10.1155/2012/986725.
40. Larsen, A.K.; Ouaret, D.; El Ouadrani, K.; Petitprez, A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol. Ther. 2011, 131, 80-90.
41. Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.